{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:03:37Z","timestamp":1793192617342,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40265-019-01148-3","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T12:54:30Z","timestamp":1561467270000},"page":"1135-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":223,"title":["Dapagliflozin: A Review in Type 2 Diabetes"],"prefix":"10.1007","volume":"79","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"issue":"1","key":"1148_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"5","key":"1148_CR2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","volume":"9","author":"J Wilding","year":"2018","unstructured":"Wilding J, Fernando K, Milne N, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):1757\u201373.","journal-title":"Diabetes Ther."},{"issue":"1","key":"1148_CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs."},{"issue":"17","key":"1148_CR4","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2165\/11209910-000000000-00000","volume":"72","author":"GL Plosker","year":"2012","unstructured":"Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289\u2013312.","journal-title":"Drugs."},{"issue":"18","key":"1148_CR5","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191\u2013209.","journal-title":"Drugs."},{"issue":"5","key":"1148_CR6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145\u20139.","journal-title":"J Med Chem."},{"key":"1148_CR7","unstructured":"AstraZeneca. Forxiga (dapagliflozin): summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en . Accessed 4 Jun 2019."},{"issue":"5","key":"1148_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2\u00a0weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513\u20139.","journal-title":"Clin Pharmacol Ther."},{"issue":"9733","key":"1148_CR9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223\u201333.","journal-title":"Lancet."},{"issue":"Suppl 1","key":"1148_CR10","first-page":"A286","volume":"65","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Kurlyandskaya R, Xu J, et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Diabetes. 2016;65(Suppl 1):A286.","journal-title":"Diabetes."},{"issue":"6 Suppl 1","key":"1148_CR11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","volume":"40","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 2014;40(6 Suppl 1):S4\u201311.","journal-title":"Diabetes Metab."},{"issue":"4","key":"1148_CR12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/00325481.2016.1173514","volume":"128","author":"N Skolnik","year":"2016","unstructured":"Skolnik N, Bonnes H, Yeh H, et al. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C. Postgrad Med. 2016;128(4):356\u201363.","journal-title":"Postgrad Med."},{"issue":"7","key":"1148_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40266-016-0382-1","volume":"33","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Mansfield TA, Ptaszynska A, et al. Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb\/III studies. Drugs Aging. 2016;33(7):511\u201322.","journal-title":"Drugs Aging."},{"issue":"4","key":"1148_CR14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962\u201371.","journal-title":"Kidney Int."},{"issue":"2","key":"1148_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","volume":"25","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25(2):93\u2013103.","journal-title":"Blood Press."},{"issue":"3","key":"1148_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"1148_CR17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252\u201362.","journal-title":"J Am Geriatr Soc."},{"issue":"7","key":"1148_CR18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TWA, et al. Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218\u201327.","journal-title":"Diabetes Care."},{"issue":"3","key":"1148_CR19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"1148_CR20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2\u00a0years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159\u201369.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"1148_CR21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/dom.12666","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18(8):766\u201374.","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"1148_CR22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jdiacomp.2017.02.001","volume":"31","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Gause-Nilsson I, Xu J, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complicat. 2017;31(7):1215\u201321.","journal-title":"J Diabetes Complicat"},{"issue":"11","key":"1148_CR23","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018;20(11):2532\u201340.","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"1148_CR24","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/dom.13473","volume":"20","author":"R Scott","year":"2018","unstructured":"Scott R, Morgan J, Zimmer Z, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876\u201384.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1148_CR25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u2013357.","journal-title":"N Engl J Med"},{"issue":"5","key":"1148_CR26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.13217","volume":"20","author":"I Raz","year":"2018","unstructured":"Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: participants\u2019 baseline characteristics. Diabetes Obes Metab. 2018;20(5):1102\u201310.","journal-title":"Diabetes Obes Metab."},{"issue":"22","key":"1148_CR27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med."},{"issue":"8","key":"1148_CR28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"Ofri Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019. doi: https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9 .","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"22","key":"1148_CR29","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 trial. Circulation. 2019;139(22):2516\u201327.","journal-title":"Circulation."},{"issue":"22","key":"1148_CR30","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528\u201336.","journal-title":"Circulation."},{"issue":"Suppl 1","key":"1148_CR31","first-page":"189","volume":"34","author":"J Wilding","year":"2017","unstructured":"Wilding J, Bailey C, Rigney U, et al. Dapagliflozin therapy for type 2 diabetes in primary care: effects on HbA1c, weight and blood pressure over two years follow-up [abstract no. P508]. Diabet Med. 2017;34(Suppl 1):189.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"1148_CR32","first-page":"A330","volume":"66","author":"H Huang","year":"2017","unstructured":"Huang H, Bell K, Gani R, et al. A retrospective real-world study of dapagliflozin vs. other oral antidiabetic therapies added to metformin in patients with type 2 diabetes (T2D) [abstract no. 1233-P]. Diabetes. 2017;66(Suppl 1):A330.","journal-title":"Diabetes"},{"issue":"4","key":"1148_CR33","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s13300-018-0470-9","volume":"9","author":"E Han","year":"2018","unstructured":"Han E, Kim A, Lee SJ, et al. Characteristics of dapagliflozin responders: a longitudinal, prospective, nationwide dapagliflozin surveillance study in Korea. Diabetes Ther. 2018;9(4):1689\u2013701.","journal-title":"Diabetes Ther."},{"issue":"Suppl 2","key":"1148_CR34","first-page":"S155","volume":"38","author":"V Viswanathan","year":"2018","unstructured":"Viswanathan V, Singh KP. Usage of dapagliflozin, a sodium glucose co-transporter inhibitor, in the management of type-2 diabetes mellitus: a real world evidence study in Indian patients (FOREFRONT) [abstract no. PP50]. Int J Diabetes Dev Ctries. 2018;38(Suppl 2):S155.","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"Suppl. 1","key":"1148_CR35","first-page":"A347","volume":"66","author":"RE Brown","year":"2017","unstructured":"Brown RE, Abitbol A, Aronson R. Real-world health outcomes of dapagliflozin vs. a DPP-4 inhibitor or a sulfonylurea in type 2 diabetes. Diabetes. 2017;66(Suppl. 1):A347.","journal-title":"Diabetes"},{"issue":"7","key":"1148_CR36","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13280","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Zatti G, Baldi I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes Metab. 2018;20(7):1781\u20136.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"1148_CR37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","volume":"20","author":"F Persson","year":"2018","unstructured":"Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20(2):344\u201351.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"1148_CR38","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"S Jabbour","year":"2018","unstructured":"Jabbour S, Seufert J, Scheen A, et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab. 2018;20(3):620\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1148_CR39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, et al. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531\u201341.","journal-title":"Diabet Med."},{"issue":"11","key":"1148_CR40","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","volume":"14","author":"O Ljunggren","year":"2012","unstructured":"Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990\u20139.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"1148_CR41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13300-015-0128-9","volume":"6","author":"A Ptaszynska","year":"2015","unstructured":"Ptaszynska A, Cohen SM, Messing EM, et al. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a \u2018case study\u2019. Diabetes Ther. 2015;6(3):357\u201375.","journal-title":"Diabetes Ther."},{"key":"1148_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","volume":"15","author":"C Sonesson","year":"2016","unstructured":"Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"1148_CR43","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"1148_CR44","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019 [web annotation]. Diabetes Care. 2019;42(Suppl 1):S90\u2013102.","journal-title":"Diabetes Care"},{"issue":"34","key":"1148_CR45","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288\u201396.","journal-title":"Eur Heart J."},{"issue":"10","key":"1148_CR46","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","volume":"61","author":"BC Lupsa","year":"2018","unstructured":"Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118\u201325.","journal-title":"Diabetologia."},{"issue":"7","key":"1148_CR47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med."},{"issue":"10166","key":"1148_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet."},{"issue":"10","key":"1148_CR49","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia."},{"issue":"1","key":"1148_CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.13492","volume":"21","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ, Marx N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes Metab. 2019;21(1):3\u201314.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1148_CR51","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dme.13898","volume":"36","author":"H Hussein","year":"2019","unstructured":"Hussein H, Zaccardi F, Khunti K, et al. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabet Med. 2019;36(4):444\u201352.","journal-title":"Diabet Med."},{"issue":"2","key":"1148_CR52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.003","volume":"45","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab. 2019;45(2):110\u201321.","journal-title":"Diabetes Metab."},{"issue":"3","key":"1148_CR53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation."},{"issue":"22","key":"1148_CR54","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","volume":"71","author":"MA Cavender","year":"2018","unstructured":"Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497\u2013506.","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"1148_CR55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709\u201317.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"23","key":"1148_CR56","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"1148_CR57","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.12543","volume":"17","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, et al. Durability and tolerability of dapagliflozin over 52\u00a0weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015;17(11):1075\u201384.","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"1148_CR58","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/dom.12737","volume":"18","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Herrera Marmolejo M, Gonzalez Gonzalez JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52\u00a0weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11):1134\u20137.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 1","key":"1148_CR59","first-page":"S380","volume":"61","author":"T Vilsboll","year":"2018","unstructured":"Vilsboll T, Ekholm E, Johnsson E, et al. Efficacy of dapagliflozin plus saxagliptin vs insulin glargine at 52\u00a0weeks in patients with type 2 diabetes inadequately controlled by metformin with or without sulfonylurea [abstract no. 775]. Diabetologia. 2018;61(Suppl 1):S380.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"1148_CR60","first-page":"LB29","volume":"67","author":"S Jabbour","year":"2018","unstructured":"Jabbour S, Guja C, Hardy E, et al. DURATION-8 randomized controlled trial 104-week results-once-weekly exenatide (EXQW) plus once-daily dapagliflozin (DAPA) vs. Exqw or DAPA alone [abstract no. 104-LB]. Diabetes. 2018;67(Suppl 1):LB29\u201330.","journal-title":"Diabetes"},{"issue":"12","key":"1148_CR61","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Frias","year":"2016","unstructured":"Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28\u00a0week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004\u201316.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"1148_CR62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","volume":"38","author":"S Matthaei","year":"2015","unstructured":"Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365\u201372.","journal-title":"Diabetes Care."},{"issue":"11","key":"1148_CR63","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009\u201317.","journal-title":"Diabetes Care."},{"issue":"11","key":"1148_CR64","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1111\/dom.13437","volume":"20","author":"D M\u00fcller-Wieland","year":"2018","unstructured":"M\u00fcller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(11):2598\u2013607.","journal-title":"Diabetes Obes Metab."},{"key":"1148_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13594","author":"Y Handelsman","year":"2018","unstructured":"Handelsman Y, Mathieu C, Del Prato S, et al. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018. https:\/\/doi.org\/10.1111\/dom.13594 .","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"1148_CR66","first-page":"A70","volume":"67","author":"T Vilsboll","year":"2018","unstructured":"Vilsboll T, Ekholm E, Johnsson EK, et al. Dapagliflozin plus saxagliptin shows noninferior A1C reduction vs. insulin glargine in patients with type 2 diabetes inadequately controlled by metformin with or without sulfonylurea. Diabetes. 2018;67(Suppl 1):A70.","journal-title":"Diabetes"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01239-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01148-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T18:51:02Z","timestamp":1694976662000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01148-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01148-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01239-1","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"25 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Dapagliflozin: A Review in Type 2 Diabetes, written by Sohita Dhillon","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}